Skip to content

    Travere Therapeutics (TVTX) stock price & financials

    View TVTX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+276.5% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $62.90M
    $74.79M
    $81.73M
    $114.45M
    $164.86M
    +162.1%
    $129.69M
    +73.4%
    $127.20M
    +55.6%
    $169.58M
    +48.2%
    Strengthening
    Operating Profit
    -$56.15M
    -$60.74M
    -$42.67M
    -$12.65M
    $24.93M
    -$32.43M
    +46.6%
    -$36.91M
    +13.5%
    $3.95M
    Strengthening
    Net Profit
    -$54.81M
    -$60.26M
    -$41.23M
    -$12.76M
    $25.71M
    $2.73M
    -$37.10M
    +10.0%
    -$34.80M
    -172.8%
    Weakening
    EPS
    $-0.70
    $-0.47
    $-0.14
    $0.29
    $-0.40
    +14.9%
    $-0.37
    -164.3%
    Weakening
    Other Income
    $1.31M
    $397.0K
    $1.49M
    -$85.0K
    $783.0K
    -40.4%
    $11.37M
    +2763.0%
    $193.0K
    -87.0%
    -$38.95M
    -45729.4%
    Weakening
    Interest
    $2.78M
    $2.82M
    $2.86M
    $2.85M
    $2.75M
    -0.9%
    $2.29M
    -18.6%
    $2.30M
    -19.5%
    $2.13M
    -25.0%
    Weakening
    Depreciation
    Profit before Tax
    -$54.84M
    -$60.34M
    -$41.19M
    -$12.73M
    $25.71M
    -$21.07M
    +65.1%
    -$36.72M
    +10.8%
    -$35.00M
    -174.8%
    Weakening
    MarginsOPM
    -89.3%
    -81.2%
    -52.2%
    -11.1%
    15.1%
    -25.0%
    +69.2%
    -29.0%
    +44.4%
    2.3%
    Strengthening
    Tax
    0.1%
    0.1%
    -0.1%
    -0.2%
    0.0%
    -80.0%
    -4.4%
    -3741.7%
    0.3%
    0.6%
    Weakening
    ReturnsROIC
    3.5%
    3.9%
    2.7%
    0.8%
    -1.7%
    -146.9%
    -0.2%
    -104.5%
    2.4%
    -10.0%
    2.3%
    +172.8%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$102.87M$62.44M$84.77M$165.75M$61.69M$58.18M$58.53M$93.03M$117.73M
    Short-Term Investments
    Total Current Assets$495.68M$429.06M$410.41M$582.83M$486.44M$616.77M$416.70M$437.56M$615.14M
    Net PP&E$3.15M$9.89M$35.09M$34.30M$30.05M$25.54M$19.63M$14.60M$11.98M
    Goodwill$936.0K$936.0K$900.0K$900.0K$800.0K$800.0K$800.0K
    Intangibles$186.69M$157.20M$154.13M$148.44M$97.07M$104.44M$103.97M$113.87M$131.52M
    Total Assets$709.16M$604.80M$607.44M$776.63M$672.59M$788.91M$594.13M$605.19M$799.36M
    LiabilitiesTotal Current Liabilities$104.62M$95.45M$92.66M$124.09M$142.16M$177.91M$200.75M$159.90M$152.03M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$7.39M$28.34M$31.50M$27.51M$22.61M$17.19M$11.13M$7.96M
    Total Liabilities$390.91M$383.60M$396.23M$474.52M$629.73M$588.10M$535.05M$490.36M$774.84M
    EquityCommon Stock & APIC$4.0K$4.0K$5.0K$6.0K$6.0K$7.0K$9.0K$9.0K$9.0K
    Retained Earnings-$270.02M-$416.44M-$585.88M-$765.97M-$1.01B-$1.13B-$1.45B-$1.47B-$1.54B
    Total Equity$318.25M$221.20M$211.21M$302.11M$42.85M$200.81M$59.08M$114.83M$24.52M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$24.96M-$58.21M-$42.74M-$14.79M-$186.29M-$280.02M-$237.47M$37.78M$92.70M
    Cash from Investing-$203.29M$19.86M-$61.33M-$137.62M-$32.55M$55.78M$99.33M$27.89M-$202.99M
    Cash from Financing$231.86M-$2.08M$127.71M$231.68M$117.57M$218.75M$139.42M-$33.47M$153.06M
    SummaryCapital Expenditure-$727.0K-$195.0K-$6.77M-$5.10M-$191.0K-$668.0K
    Free Cash Flow-$25.68M-$58.41M-$49.51M-$19.89M-$186.48M-$280.69M
    FCF Margin-15.6%-33.3%-25.0%-15.1%-170.4%-193.3%

    Ratios